Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Clinical trial NCT01609816 · TERMINATED

Trial details

NCT number: NCT01609816
Sponsor: Barbara Ann Karmanos Cancer Institute
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Hodgkin's Lymphoma Multiple Mycosis Fungoides Hodgkin's Lymphoma Multiple Myeloma

Start date: 2015-02-12
Primary completion: 2018-10-09
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.